ArticleACS infectious diseases2018
Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis.
Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Shared urinary metabolomic signatures as potential biomarkers for early intestinalCurrent research in parasitology & vector-borne diseases · 2026Article
- Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics.PLoS neglected tropical diseases · 2024Article
- Cytotoxicity Activity, Metabolite Profiling, and Isolation Compound from Crude Hexane Extract of Cleome rutidospermae.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Immobilized Enzymes on Magnetic Beads for Separate Mass Spectrometric Investigation of Human Phase II Metabolite Classes.Analytical chemistry · 2023Article
- Factors influencing community acceptability of mass drug administration for the elimination of onchocerciasis in the Asante Akim South Municipal, Ghana.PLoS neglected tropical diseases · 2023Article
- Untargeted serum metabolomics analysis of Trichinella spiralis-infected mouse.PLoS neglected tropical diseases · 2023Article
- Point-of-Care Monitoring of Respiratory Diseases Using Lateral Flow Assay and CMOS Camera Reader.IEEE journal of translational engineering in health and medicine · 2022Article
- Whole blood transcriptome analysis in onchocerciasis.Current research in parasitology & vector-borne diseases · 2022Article
- Multimodal biomarker discovery for active Onchocerca volvulus infection.PLoS neglected tropical diseases · 2021Article
- Urine metabolites for the identification of Onchocerca volvulus infections in patients from Cameroon.Parasites & vectors · 2021Article
- Areas of Metabolomic Exploration for Helminth Infections.ACS infectious diseases · 2021Article
- Article
- NTD Diagnostics for Disease Elimination: A Review.Diagnostics (Basel, Switzerland) · 2020Review
- Urinary N-acetyltyramine-O,β-glucuronide in Persons with OnchocerciasisPathogens (Basel, Switzerland) · 2020Article
- Community Participation in and Perception of Community-Directed Treatment with Ivermectin in Kinshasa, DRC.Tropical medicine and infectious disease · 2019Article
- Performance evaluation of 3 serodiagnostic peptide epitopes and the derived multi-epitope peptide OvNMP-48 for detection of Onchocerca volvulus infection.Parasitology research · 2019Article
- Review of the National Program for Onchocerciasis Control in the Democratic Republic of the Congo.Tropical medicine and infectious disease · 2019Review
- Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.EC microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The parasitic disease onchocerciasis is the second leading cause of preventable blindness, afflicting more than 18 million people worldwide. Despite an available treatment, ivermectin, and control efforts by the World Health Organization, onchocerciasis remains a burden in many regions. With an estimated 120 million people living in areas at risk of infection, efforts are now shifting from prevention to surveillance and elimination. The lack of a robust, point-of-care diagnostic for an active Onchocerca infection has been a limiting factor in these efforts. Previously, we reported the discovery of the biomarker N-acetyl-tyramine- O-glucuronide (NATOG) in human urine samples and its ability to track treatment progression between medicated patients relative to placebo; we also established its capability to monitor disease burden in a jird model. NATOG is a human-produced metabolite of tyramine, which itself is produced as a nematode neurotransmitter. The ability of NATOG to distinguish between active and past infection overcomes the limitations of antibody biomarkers and PCR methodologies. Lateral flow immunoassay (LFIA) diagnostics offer the versatility and simplicity to be employed in the field and are inexpensive enough to be utilized in large-scale screening efforts. Herein, we report the development and assessment of a NATOG-based urine LFIA for onchocerciasis, which accurately identified 85% of analyzed patient samples ( N = 27).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.